Drug resistance in Leishmania: similarities and differences to other organisms

Drug Resistance Updates

Volumn 1, Issue 4, 1998, Pages 266-278

  Papadopoulou, Barbara ^a   Kündig, Christoph ^a   Singh, Ajay ^a   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002940232     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80007-1     Document Type: Review

References (157)

1. Ashford R.W., Desjeux P., and deRaadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8 (1992) 104-105
2. Magill A.J., Grogl M., Gasser Jr. R.A., et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 328 19 (1993) 1383-1387
3. Ouellette M., and Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitol Today 9 5 (1993) 150-153
4. Alvar J., Canavate C., Gutierrez-Solar B., et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10 2 (1997) 298-319
5. Reiner S.L., and Locksley R.M. The regulation of immunity to Leishmania major. Annu Rev Immunol 13 (1995) 151-177
6. Olliaro P.L., and Bryceson A. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9 (1993) 323-328
7. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24 4 (1997) 684-703
8. Borst P., and Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 49 (1995) 427-460
9. Grogl M., Thomason T.N., and Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 47 1 (1992) 117-126
10. Pt2. Basselin M., Lawrence F., and Robert-Gero M. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem J 315 (1996) 631-634
11. Basselin M., Badet-Denisot M.A., Lawrence F., and Robert-Gero M. Effects of pentamidine on polyamine level and biosynthesis in wild-type, pentamidine-treated, and pentamidine-resistant Leishmania. Exp Parasitol 85 3 (1997) 274-282
12. Fairlamb A.H., and Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 46 (1992) 695-729
13. Mishra M., Biswas U.K., Jha A.M., and Khan A.B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian Kala-azar. Lancet 344 8937 (1994) 1599-1600
14. Berman J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 10 3 (1988) 560-586
15. Maarouf M., Lawrence F., Croft S.L., and Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 81 5 (1995) 421-425
16. Maarouf M., de Kouchkovsky Y., Brown S., et al. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 232 2 (1997) 339-348
17. Soto J., Fuya P., Herrera R., and Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26 1 (1998) 56-58
18. Ullman B., and Carter D. Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. Int J Parasitol 27 2 (1997) 203-213
19. Reed S.G. Scott P.T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5 4 (1993) 524-531
20. discussion. Locksley R.M., Wakil A.E., Corry D.B., et al. The development of effector T cell subsets in murine Leishmania major infection. Ciba Found Symp 195 (1995) 110-117
21. Locksley R.M., Wakil A.E., Corry D.B., et al. The development of effector T cell subsets in murine Leishmania major infection. Ciba Found Symp 195 (1995) 117-122
22. Badaro R., Falcoff E., Badaro F.S., et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma [see comments]. N Engl J Med 322 1 (1990) 16-21
23. Sundar S., and Murray H.W. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis 172 6 (1995) 1627-1629
24. Jackson J.E., Tally J.D., Ellis W.Y., et al. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 43 5 (1990) 464-480
25. Mukhopadhyay R., Dey S., Xu N., et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A 93 19 (1996) 10383-10387
26. Grondin K., Haimeur A., Mukhopadhyay R., et al. Co-amplification of the gamma-glutamylcysteine synthetase gene gshl/it and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. Embo J 16 11 (1997) 3057-3065
27. Legare D., Papadopoulou B., Roy G., et al. Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp Parasitol 87 3 (1997) 275-282
28. Ouellette M., Légaré D., Haimeur A., et al. ABC transporters in Leishmania and their role in drug resistance. Drug Res. Updates 1 (1998) 43-48
29. in press. Haimeur A., and Ouellette M. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrob. Agents Chemother. (1998)
30. Rosen B.P. Resistance mechanisms to arsenicals and antimonials. J Basic Clin Physiol Pharmacol 6 3-4 (1995) 251-263
31. Carter N.S., and Fairlamb A.H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter [published erratum appears in Nature 1993 Jan 28; 361 (6410): 374]. Nature 361 6408 (1993) 173-176
32. (Yu VL, ed. Antimicrobial Chemotherapy; vol in press). Ouellette M., and Pépin J. Pentamidine (1998), Williams and Wilkins
33. Calonge M., Johnson R., Balana-Fouce R., and Ordonez D. Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. Biochem Pharmacol 52 6 (1996) 835-841
34. Basselin M., Lawrence F., and Robert-Gero M. Altered transport properties of pentamidine-resistant Leishmania donovani and L. amazonensis promastigotes. Parasitol Res 83 5 (1997) 413-418
35. Bitonti A.J., Dumont J.A., and McCann P.P. Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochem J 237 3 (1986) 685-689
36. Berger B.J., Carter N.S., and Fairlamb A.H. Polyamine and pentamidine metabolism in African trypanosomes. Acta Trop 54 3-4 (1993) 215-224
37. Sereno D., and Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41 5 (1997) 972-976
38. Basselin M., and Robert-Gero M. Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol Res 84 1 (1998) 78-83
39. Pt 2. Le Quesne S.A., and Fairlamb A.H. Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes. Biochem J 316 (1996) 481-486
40. Bacchi C.J., and Yarlett N. Effects of antagonists of polyamine metabolism on African trypanosomes. Acta Trop 54 3-4 (1993) 225-236
41. Carter N.S., Berger B.J., and Fairlamb A.H. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen- sensitive and - resistant Trypanosoma bruceibrucei. J Biol Chem 270 47 (1995) 28153-28157
42. Berger B.J., Carter N.S., and Fairlamb A.H. Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Mol Biochem Parasitol 69 2 (1995) 289-298
43. Tabor C.W., and Tabor H. Polyamines. Annu Rev Biochem 53 (1984) 749-790
44. Fairlamb A.H., Carter N.S., Cunningham M., and Smith K. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 53 1-2 (1992) 213-222
45. McCann P.P., and Pegg A.E. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 54 2 (1992) 195-215
46. (Yu VL, ed. Antimicrobial Chemotherapy; vol in press). Ouellette M., and Pépin J. Eflornithine (1998), Williams and Wilkins, New York
47. Pt B. Kaur K., Iovannisci D.M., and Ullman B. Adenine phosphoribosyltransferase-deficient Leishmania donovani. Adv Exp Med Biol 195 (1986) 553-557
48. Bitonti A.J., McCann P.P., and Sjoerdsma A. Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol 64 2 (1987) 237-243
49. Mukhopadhyay R., and Madhubala R. Effect of antioxidants on the growth and polyamine levels of Leishmania donovani. Biochem Pharmacol 47 4 (1994) 611-615
50. Fairlamb A.H., and Sa L.Q. Polyamine metabolism in Trypanosomes. In: Hide G., Mottram J.C., Coombs G.H., and Ph H. (Eds). CAB International (1997)
51. Li F., Hua S.B., Wang C.C., and Gottesdiener K.M. Procyclic Trypanosoma brucei cell lines deficient in ornithine decarboxylase activity. Mol Biochem Parasitol 78 1-2 (1996) 227-236
52. Iten M., Mett H., Evans A., et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L- alpha-difluoromethylornithine. Antimicrob Agents Chemother 41 9 (1997) 1922-1925
53. Coons T., Hanson S., Bitonti A.J., et al. Alpha-difluoromethylornithine resistance in Leishmania donovani is associated with increased ornithine decarboxylase activity. Mol Biochem Parasitol 39 1 (1990) 77-89
54. Mukhopadhyay R., Kapoor P., and Madhubala R. Characterization of alpha-difluoromethylornithine resistant Leishmania donovani and its susceptibility to other inhibitors of the polyamine biosynthetic pathway. Pharmacol Res 34 1-2 (1996) 43-46
55. Hanson S., Beverley S.M., Wagner W., and Ullman B. Unstable amplification of two extrachromosomal elements in alpha-difluoromethylornithine-resistant Leishmania donovani. Mol Cell Biol 12 12 (1992) 5499-5507
56. Pt 3. Sanchez C.P., Mucci J., Gonzalez N.S., et al. Alpha-difluoromethylornithine-resistant cell lines obtained after one- step selection of Leishmania mexicana promastigote cultures. Biochem J 324 (1997) 847-853
57. Phillips M.A., Coffino P., and Wang C.C. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. J Biol Chem 262 18 (1987) 8721-8727
58. Bellofatto V., Fairlamb A.H., Henderson G.B., and Cross G.A. Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Mol Biochem Parasitol 25 3 (1987) 227-238
59. Berman J.D., Goad L.J., Beach D.H., and Holz Jr. G.G. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 20 1 (1986) 85-92
60. Hart D.T., Lauwers W.J., Willemsens G., et al. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol Biochem Parasitol 33 2 (1989) 123-134
61. Sokol-Anderson M.L., Brajtburg J., and Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 154 1 (1986) 76-83
62. Abu-Salah K.M., Sedrani S.H., Tobia A.S., and Gambo H.A. Influence of amphotericin B on the transport of phosphate, sulphate and potassium ions across the human erythrocyte membrane. Acta Haematol 79 2 (1988) 77-80
63. Vertut-Doi A., Hannaert P., and Bolard J. The polyene antibiotic amphotericin B inhibits the Na+/K+ pump of human erythrocytes. Biochem Biophys Res Commun 157 2 (1988) 692-697
64. Vertut-Doi A., Ishiwata H., and Miyajima K. Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Biochim Biophys Acta 1278 1 (1996) 19-28
65. Dietze R., Fagundes S.M., Brito E.F., et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 89 3 (1995) 309-311
66. Thakur C.P., Pandey A.K., Sinha G.P., et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 90 3 (1996) 319-322
67. Mbongo N., Loiseau P.M., Billion M.A., and Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 42 2 (1998) 352-357
68. Nolte F.S., Parkinson T., Falconer D.J., et al. Isolation and characterization of fluconazole- and amphotericin B- resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 41 1 (1997) 196-199
69. Warnock D.W. Amphotericin B: an introduction. J Antimicrob Chemother 28 Suppl B (1991) 27-38
70. Joseph-Horne T., Hollomon D., Loeffler R.S., and Kelly S.L. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 39 7 (1995) 1526-1529
71. Sanglard D., Kuchler K., Ischer F., et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39 11 (1995) 2378-2386
72. Ouellette M., and Kündig C. Microbial multidrug resistance. Internat J Antimicrob Agents 8 (1997) 179-187
73. Hay R.J. Antifungal therapy and the new azole compounds. J Antimicrob Chemother 28 Suppl A (1991) 35-46
74. Suppl. Urbina J.A. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114 (1997) S91-S99
75. Beach D.H., Goad L.J., and Holz Jr. G.G. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 31 2 (1988) 149-162
76. Rangel H., Dagger F., Hernandez A., et al. Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes [published erratum appears in Antimicrob Agents Chemother 1997 Feb; 41 (2): 496]. Antimicrob Agents Chemother 40 12 (1996) 2785-2791
77. White T.C. Increased mRNA levels of ERG16, CDR, and MDRI correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41 7 (1997) 1482-1487
78. White T.C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother 41 7 (1997) 1488-1494
79. Sanglard D., Ischer F., Koymans L., and Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha- demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents [In Process Citation]. Antimicrob Agents Chemother 42 2 (1998) 241-253
80. Vanden Bossche H., Marichal P., and Odds F.C. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2 10 (1994) 393-400
81. Ramos H., Saint-Pierre-Chazalet M., Bolard J., and Cohen B.E. Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes. Antimicrob Agents Chemother 38 5 (1994) 1079-10784
82. Marr J.J. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J Lab Clin Med 118 2 (1991) 111-119
83. Velez I., Agudelo S., Hendrickx E., et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126 3 (1997) 232-236
84. Hwang H.Y., and Ullman B. Genetic analysis of purine metabolism in Leishmania donovani. J Biol Chem 272 31 (1997) 19488-194896
85. Pfefferkorn E.R., and Borotz S.E. Toxoplasma gondii: characterization of a mutant resistant to 6-thioxanthine. Exp Parasitol 79 3 (1994) 374-382
86. Iovannisci D.M., Kaur K., Young L., and Ullman B. Genetic analysis of nucleoside transport in Leishmania donovani. Mol Cell Biol 4 6 (1984) 1013-1019
87. Rainey P., and Santi D.V. Formycin B resistance in Leishmania. Biochem Pharmacol 33 8 (1984) 1374-1374
88. Aronow B., Kaur K., McCartan K., and Ullman B. Two high affinity nucleoside transporters in Leishmania donovani. Mol Biochem Parasitol 22 1 (1987) 29-37
89. Finley R.W., Cooney D.A., and Dvorak J.A. Nucleoside uptake in Trypanosoma cruzi: analysis of a mutant resistant to tubercidin. Mol Biochem Parasitol 31 2 (1988) 133-140
90. Nozaki T., and Dvorak J.A. Molecular biology studies of tubercidin resistance in Trypanosoma cruzi. Parasitol Res 79 6 (1993) 451-455
91. Hedstrom L., and Wang C.C. Purine base transport in wild-type and mycophenolic acid-resistant Tritrichomonas foetus. Mol Biochem Parasitol 35 3 (1989) 219-227
92. Ross C.A., and Barns A.M. Alteration to one of three adenosine transporters is associated with resistance to cymelarsan in Trypanosoma evansi. Parasitol Res 82 2 (1996) 183-188
93. Barrett M.P., Zhang Z.Q., Denise H., et al. A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol Biochem Parasitol 73 1-2 (1995) 223-229
94. Kerby B.R., and Detke S. Reduced purine accumulation is encoded on an amplified DNA in Leishmania mexicana amazonensis resistant to toxic nucleosides. Mol Biochem Parasitol 60 2 (1993) 171-185
95. Detke S. Identification of a transcription factor like protein at the TOR locus in Leishmania mexicana amazonensis. Mol Biochem Parasitol 90 2 (1997) 505-511
96. Wilson K., Beverley S.M., and Ullman B. Stable amplification of a linear extrachromosomal DNA in mycophenolic acid-resistant Leishmania donovani. Mol Biochem Parasitol 55 1-2 (1992) 197-206
97. Wilson K., Berens R.L., Sifri C.D., and Ullman B. Amplification of the inosinate dehydrogenase gene in Trypanosoma brucei gambiense due to an increase in chromosome copy number. J Biol Chem 269 46 (1994) 28979-28987
98. Ferone R., and Roland S. Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata. Proc Natl Acad Sci U S A 77 10 (1980) 5802-5806
99. in press. Ouellette M., Leblanc É., Kündig C., and Papadopoulou B. Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites. In: Rosen B.P., and Mobashery S. (Eds). Resolving the antibiotic paradox (1998), Plenum Publishing Corporation, New York
100. Campbell C.C., Collins W.E., Milhous W.K., et al. Adaptation of the Indochina I/CDC strain of Plasmodium falciparum to the squirrel monkey (Saimiri sciureus). Am J Trop Med Hyg 35 3 (1986) 472-475
101. Nzila-Mounda A., Mberu E.K., Sibley C.H., et al. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 42 1 (1998) 164-169
102. Nare B., Hardy L.W., and Beverley S.M. The roles of pteridine reductase I and dihydrofolate reductase- thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem 272 21 (1997) 13883-13891
103. Coderre J.A., Beverley S.M., Schimke R.T., and Santi D.V. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci U S A 80 8 (1983) 2132-2136
104. Beverley S.M., Coderre J.A., Santi D.V., and Schimke R.T. Unstable DNA amplifications in methotrexate-resistant Leishmania consist of extrachromosomal circles which relocalize during stabilization. Cell 38 2 (1984) 431-439
105. Arrebola R., Olmo A., Reche P., et al. Isolation and characherization of a mutant dihydrofolate reductase-thymidylate synthase from methotrexate-resistant Leishmania cells. J Biol Chem 269 14 (1994) 10590-10596
106. Huovinen P., Sundstrom L., Swedberg G., and Skold O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 39 2 (1995) 279-289
107. Bertino J.R. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11 1 (1993) 5-14
108. Huennekens F.M. In search of dihydrofolate reductase. Protein Sci 5 6 (1996) 1201-1208
109. Cowman A.F., Morry M.J., Biggs B.A., Cross G.A., and Foote S.J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 85 23 (1988) 9109-9113
110. Wang J., Leblanc E., Chang C.F., et al. Pterin and folate reduction by the Leishmania tarentolae H locus short- chain dehydrogenase/reductase PTRI. Arch Biochem Biophys 342 2 (1997) 197-202
111. Ellenberger T.E., and Beverley S.M. Reductions in methotrexate and folate influx in methotrexate-resistant lines of Leishmania major are independent of R or H region amplification. J Biol Chem 262 28 (1987) 13501-13506
112. Papadopoulou B., Roy G., and Ouellette M. Frequent amplification of a short chain dehydrogenase gene as part of circular and linear amplicons in methotrexate resistant Leishmania. Nucleic Acids Res 21 18 (1993) 4305-4312
113. Olmo A., Arrebola R., Bernier V., et al. Co-existence of circular and multiple linear amplicons in methotrexate- resistant Leishmania. Nucleic Acids Res 23 15 (1995) 2856-2864
114. Papadopoulou B., Roy G., and Ouellette M. A novel antifolate resistance gene on the amplified H circle of Leishmania. Embo J 11 10 (1992) 3601-3608
115. Callahan H.L., and Beverley S.M. A member of the aldoketo reductase family confers methotrexate resistance in Leishmania. J Biol Chem 267 34 (1992) 24165-24168
116. Papadopoulou B., Roy G., Mourad W., et al. Changes in folate and pterin metabolism after disruption of the Leishmania H locus short chain dehydrogenase gene. J Biol Chem 269 10 (1994) 7310-7315
117. Bello A.R., Nare B., Freedman D., et al. PTRI: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S A 91 24 (1994) 11442-11446
118. Leblanc E., Papadopoulou B., Bernatchez C., and Ouellette M. Residues involved in co-factor and substrate binding of the short-chain dehydrogenase/reductase PTRI producing methotrexate resistance in Leishmania. Eur J Biochem 251 3 (1998) 768-774
119. Hardy L.W., Matthews W., Nare B., and Beverley S.M. Biochemical and Genetic Tests for Inhibitors of Leishmania Pteridine Pathways. Exp Parasitol 87 3 (1997) 158-170
120. Robello C., Navarro P., Castanys S., and Gamarro F. A pteridine reductase gene ptrl contiguous to a P-glycoprotein confers resistance to antifolates in Trypanosoma cruzi. Mol Biochem Parasitol 90 2 (1997) 525-535
121. Dewes H., Ostergaard H.L., and Simpson L. Impaired drug uptake in methotrexate resistant Crithidia fasciculata without changes in dihydrofolate reductase activity or gene amplification. Mol Biochem Parasitol 19 2 (1986) 149-161
122. Kaur K., Coons T., Emmett K., and Ullman B. Methotrexate-resistant Leishmania donovani genetically deficient in the folate-methotrexate transporter. J Biol Chem 263 15 (1988) 7020-7028
123. Papadopoulou B., and Ouellette M. Frequent amplification of a short chain dehydrogenase gene in methotrexate resistant Leishmania. Adv Exp Med Biol 338 (1993) 559-562
124. Gamarro F., Chiquero M.J., Amador M.V., et al. P-glycoprotein overexpression in methotrexate-resistant Leishmania tropica. Biochem Pharmacol 47 11 (1994) 1939-1947
125. Ouellette M., Papadopoulou B., Haimeur A., et al. Transport of antifolates and antimonials in drug-resistant Leishmania. In: Georgopapadakou N. (Ed). Drug Transport in Antimicrobial and anticancer chemotherapy (1995), Marcel Dekker, Inc, New York 377-402
126. Beck J.T., and Ullman B. Biopterin conversion to reduced folates by Leishmania donovani promastigotes. Mol Biochem Parasitol 49 1 (1991) 21-28
127. Suppl. Nare B., Luba J., Hardy L.W., and Beverley S. New approaches to Leishmania chemotherapy: pteridine reductase I (PTRI) as a target and modulator of antifolate sensitivity. Parasitology 114 (1997) S101-S110
128. Myler P.J., Lodes M.J., Merlin G., et al. An amplified DNA element in Leishmania encodes potential integral membrane and nucleotide-binding proteins. Mol Biochem Parasitol 66 1 (1994) 11-20
129. Segovia M., and Ortiz G. LDI amplifications in Leishmania. Parasitol Today 13 (1997) 342-348
130. Gorlick R., Goker E., Trippett T., et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89 3 (1997) 1013-1018
131. Poli A., Sozzi S., Guidi G., et al. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Vet Parasitol 71 4 (1997) 263-271
132. Fong D., Chan M.M., Rodriguez R., et al. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am J Trop Med Hyg 51 6 (1994) 758-766
133. el-On J., Sulitzeanu A., and Schnur L.F. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Ann Trop Med Parasitol 85 3 (1991) 323-328
134. Gueiros-Filho F.J., and Beverley S.M. On the introduction of genetically modified Leishmania outside the laboratory. Exp Parasitol 78 4 (1994) 425-428
135. Henderson D.M., Sifri C.D., Rodgers M., et al. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol Cell Biol 12 6 (1992) 2855-2865
136. Chow L.M., Wong A.K., Ullman B., and Wirth D.F. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol Biochem Parasitol 60 2 (1993) 195-208
137. Gueiros-Filho F.J., Viola J.P., Gomes F.C., et al. Leishmania amazonensis: Multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp Parasitol 81 4 (1995) 480-490
138. Chiquero M.J., Perez-Victoria J.M., O'Valle F., et al. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem Pharmacol 55 2 (1998) 131-139
139. Ullman B. Multidrug resistance and P-glycoproteins in parasitic protozoa. J Bioenerg Biomembr 27 1 (1995) 77-84
140. in press. vol ABC Transporters: Biochemical, cellular, and molecular aspects). Ouellette M., Haimeur A., Grondin K., et al. Amplification of the ABC transporter gene pgpA and of other metal resistance genes in Leishmania tarentolae and their study by gene transfection and gene disruption. In: Ambudkar S.V., and Gottesman M.M. (Eds). Methods Enzymol (1988), Academic Press, San Diego
141. Liu X., and Chang K.P. The 63-kilobase circular amplicon of tunicamycin-resistant Leishmania amazonensis contains a functional N-acetylglucosamine-I-phosphate transferase gene that can be used as a dominant selectable marker in transfection. Mol Cell Biol 12 9 (1992) 4112-4122
142. Beverley S.M. Gene amplification in Leishmania. Annu Rev Microbiol 45 (1991) 417-444
143. Ouellette M., Hettema E., Wust D., et al. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. Embo J 10 4 (1991) 1009-1016
144. Grondin K., Roy G., and Ouellette M. Formation of extrachromosomal circular amplicons with direct or inverted duplications in drug-resistant Leishmania tarentolae. Mol Cell Biol 16 7 (1996) 3587-3595
145. Papadopoulou B., Roy G., and Ouellette M. Autonomous replication of bacterial DNA plasmid oligomers in Leishmania. Mol Biochem Parasitol 65 1 (1994) 39-49
146. Patnaik P.K., Bellofatto V., Hartree D., and Cross G.A. An episome of Trypanosoma brucei can exist as an extrachromosomal element in a broad range of trypanosomatids but shows different requirements for stable replication. Mol Biochem Parasitol 66 1 (1994) 153-156
147. Cowman A.F., and Lew A.M. Antifolate drug selection results in duplication and rearrangement of chromosome 7 in Plasmodium chabaudi. Mol Cell Biol 9 11 (1989) 5182-5188
148. Wahl G.M. The importance of circular DNA in mammalian gene amplification. Cancer Res 49 6 (1989) 1333-1340
149. Quijada L., Soto M., Alonso C., and Requena J.M. Analysis of post-transcriptional regulation operating on transcription products of the tandemly linked Leishmania infantum hsp 70 genes. J Biol Chem 272 7 (1997) 4493-4499
150. Aly R., Argaman M., Halman S., and Shapira M. A regulatory role for the 5′ and 3′ untranslated regions in differential expression of hsp83 in Leishmania. Nucleic Acids Res 22 15 (1994) 2922-2929
151. Svensson F., Ceriani C., Wallstrom E.L., et al. Cloning of a trypanosomatid gene coding for an ornithine decarboxylase that is metabolically unstable even though it lacks the C-terminal degradation domain. Proc Natl Acad Sci U S A 94 2 (1997) 397-402
152. Pt 1. Bates P.A. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 108 (1994) 1-9
153. Roberts W.L., Berman J.D., and Rainey P.M. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 39 6 (1995) 1234-1239
154. Callahan H.L., Portal A.C., Devereaux R., and Grogl M. An axenic amastigote system for drug screening. Antimicrob Agents Chemother 41 4 (1997) 818-822
155. Ephros M., Waldman E., and Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother 41 5 (1997) 1064-1068
156. Sereno D., and Lemesre J.L. In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced. Antimicrob Agents Chemother 41 9 (1997) 1898-1903
157. Ibrahim M.E., Hag-Ali M., el-Hassan A.M., et al. Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res 80 7 (1994) 569-574